LWM
BCLI

Liberty Wealth Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Liberty Wealth Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22,666
Closed -$25.4K – 247
2025
Q2 		$25.4K Hold
22,666
– – ﹤0.01% 229
2025
Q1 		$28.6K Hold
22,666
– – 0.01% 153
2024
Q4 		$51.5K Sell
22,666
-11
-0% -$20 0.01% 213
2024
Q3 		$78K Hold
22,677
– – 0.01% 211
2024
Q2 		$115K Hold
22,677
– – 0.02% 201
2024
Q1 		$192K Hold
22,677
– – 0.04% 181
2023
Q4 		$94K Sell
22,677
-831
-4% -$2.49K 0.02% 168
2023
Q3 		$71K Buy
23,508
+13,471
+134% +$306K 0.02% 172
2023
Q2 		$310K Buy
10,037
+10
+0.1% +$414 0.08% 132
2023
Q1 		$496K Buy
+10,027
New +$291K 0.1% 128
2022
Q3 		$176K Buy
2,667
+667
+33% +$33.5K 0.05% 142
2022
Q2 		$82K Buy
+2,000
New +$90.1K 0.03% 148

Other funds holding BCLI

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BSB
Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return
VWA
VSM Wealth Advisory Hunt Valley, Maryland $376M AUM 21.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Liberty Wealth Management's BCLI Position: Q3 2025 in Review

Liberty Wealth Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 22,666 shares — an estimated $25.4K sold.

Liberty Wealth Management first reported a position in BCLI in Q2 2022 and held it in 12 quarters. The position peaked at $496K in Q1 2023. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

  • Liberty Wealth Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
  • Liberty Wealth Management sold 22,666 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $25.4K.
  • Liberty Wealth Management first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2022 and held it in 12 quarters.
  • Liberty Wealth Management's BRAINSTORM CELL THERAPUTC position peaked at $496K in Q1 2023.
  • 5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Liberty Wealth Management's 13F filing for Q3 2025, filed 31 Oct 2025.